Kymera rises on accelerated trial timeline for experimental eczema drug

Kymera Therapeutics

25/06/2026 12:49

** Shares of drug developer Kymera Therapeutics KYMR.O rise 7.8% to $107.8 premarket 
** Co says it has completed enrollment for the mid-stage trial of its experimental treatment, KT-621, to treat moderate to severe atopic dermatitis
** Enrollment finished earlier than expected, allowing Kymera to bring forward its topline data to year-end 2026 - six months ahead of the previous mid-2027 guidance - KYMR
** Co says it expects to begin late-stage trials by mid-2027 
** RBC Capital Markets says "accelerated timelines should move KYMR back onto investors' 2026 radars, and we continue to see strong prospects for 621 and upside potential for shares"
** "This speaks to the level of excitement investigators and patients have towards this new mechanism of action and an oral alternative to Regeneron's Dupixent" - J.P.Morgan 
** As of last close, stock up 28.4% YTD 

(Reporting by Siddhi Mahatole)
((siddhi.mahatole@thomsonreuters.com))